The cytoprotective drug amifostine modifies both expression and activity of the pro-angiogenic factor VEGF-A. - Archive ouverte HAL Access content directly
Journal Articles BMC Medicine Year : 2010

The cytoprotective drug amifostine modifies both expression and activity of the pro-angiogenic factor VEGF-A.

(1, 2) , (1, 2) , (3) , (1, 2) , (3) , (4) , (4) , (2, 1) , (1, 2) , (1, 2)
1
2
3
4
Roberta Sinisi
  • Function : Author
  • PersonId : 921197
Matteo Zanda
  • Function : Author
  • PersonId : 921198

Abstract

BACKGROUND: Amifostine (WR-2721, delivered as Ethyol) is a phosphorylated aminothiol compound clinically used in addition to cis-platinum to reduce the toxic side effects of therapeutic treatment on normal cells without reducing their efficacy on tumour cells. Its mechanism of action is attributed to the free radical scavenging properties of its active dephosphorylated metabolite WR-1065. However, amifostine has also been described as a potent hypoxia-mimetic compound and as a strong p53 inducer; both effects are known to potently modulate vascular endothelial growth factor (VEGF-A) expression. The angiogenic properties of this drug have not been clearly defined. METHODS: Cancer cell lines and endothelial cells were used in culture and treated with Amifostine in order to study (i) the expression of angiogenesis related genes and proteins and (ii) the effects of the drug on VEGF-A induced in vitro angiogenesis. RESULTS: We demonstrated that the treatment of several human cancer cell lines with therapeutical doses of WR-1065 led to a strong induction of different VEGF-A mRNA isoforms independently of HIF-1alpha. VEGF-A induction by WR-1065 depends on the activation of the eIF2alpha/ATF4 pathway. This up-regulation of VEGF-A mRNA was accompanied by an increased secretion of VEGF-A proteins fully active in stimulating vascular endothelial cells (EC). Nevertheless, direct treatment of EC with amifostine impaired their ability to respond to exogenous VEGF-A, an effect that correlated to the down-regulation of VEGFR-2 expression, to the reduction in cell surface binding of VEGF-A and to the decreased phosphorylation of the downstream p42/44 kinases. CONCLUSIONS: Taken together, our results indicate that amifostine treatment modulates tumour angiogenesis by two apparently opposite mechanisms - the increased VEGF-A expression by tumour cells and the inhibition of EC capacity to respond to VEGF-A stimulation.
Fichier principal
Vignette du fichier
1741-7015-8-19.pdf (1004.63 Ko) Télécharger le fichier
Vignette du fichier
1741-7015-8-19-S1.DOC (35 Ko) Télécharger le fichier
Vignette du fichier
1741-7015-8-19-S2.PDF (72 Ko) Télécharger le fichier
Vignette du fichier
1741-7015-8-19-S3.PDF (55.87 Ko) Télécharger le fichier
Vignette du fichier
1741-7015-8-19-S4.PDF (1.95 Mo) Télécharger le fichier
Vignette du fichier
1741-7015-8-19-S5.PPT (27.5 Ko) Télécharger le fichier
Vignette du fichier
1741-7015-8-19.xml (98.16 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Format : Other
Format : Other
Format : Other
Format : Other
Format : Other
Format : Other

Dates and versions

inserm-00663906 , version 1 (27-01-2012)

Identifiers

Cite

Sophie Dedieu, Xavier Canron, Hamid Reza Rezvani, Marion Bouchecareilh, Frédéric Mazurier, et al.. The cytoprotective drug amifostine modifies both expression and activity of the pro-angiogenic factor VEGF-A.. BMC Medicine, 2010, 8 (1), pp.19. ⟨10.1186/1741-7015-8-19⟩. ⟨inserm-00663906⟩

Collections

INSERM
249 View
365 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More